Press Releases

Featured Press Releases

BIO Statement on Resignation of Peter Marks from…

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary leadership of Dr. Peter Marks, the FDA…

Learn more

New survey: U.S. biotechs warn tariffs could…

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90…

Learn more

BIO Releases New Report Underscoring the Massive…

WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the significant economic impact of the U.S. bioeconomy…

Learn more

BIO Statement Regarding Nomination of Robert F. Kennedy Jr.

November 14, 2024

BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…

BIO Released the Following Statement After Yesterday’s Announcement From the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) Sharing Its Final Notice Exemption for Additional Modification Plants

November 13, 2024

“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…

BIO Statement on Lawsuit Over 340B Rebates

November 12, 2024

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…

BIO Statement on 2024 U.S. Election

November 6, 2024

WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election:“We look forward to working closely with President-elect Trump, his incoming Administration, and members of Congress on…

New Poll: Voters Want Federal Government to Invest More in Women's Health Research

October 17, 2024

WASHINGTON, DC (October 17, 2024 ) -- More than eight in ten voters believe that it's important for the National Institutes of Health to devote additional resources to understanding health conditions that primarily impact women. That's among the key…

BIO Urges Biden Administration to Work Alongside President of Mexico to Resolve Ongoing Trade Disputes Under the USMCA

October 1, 2024

The Biotechnology Innovation Organization (BIO) released the following statement in response to a bipartisan letter signed by 21 members of the U.S. House of Representatives. Led by Reps. Randy Feenstra (R-IA) and Dan Kildee (D-MI), the letter urged…

Virginia Governor Glenn Youngkin named BIO’s Governor of the Year

September 17, 2024

WASHINGTON, DC (September 17, 2024) – Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award. BIO’s annual award honors governors for their leadership and…

New Season of “I am BIO” Podcast Explores Patient Stories, Weight Loss Drugs, Food Security, and More

September 5, 2024

WASHINGTON - (September 5, 2024) –The Biotechnology Innovation Organization (BIO) will launch the fall season of the award-winning “I am BIO” podcast on September 10. Now entering its fifth year, the podcast explores the intersection of…

BIO Statement On Selected Drugs in Medicare under Inflation Reduction Act

August 15, 2024

The Biotechnology Innovation Organization (BIO) released the following statement after today’s announcement from the Centers for Medicare & Medicaid Services (CMS) on selected drugs under the Inflation Reduction Act (IRA):“While the Inflation…

Sylvia Wulf to Serve as Interim Lead of BIO's Agriculture & Environment Center of Excellence

July 25, 2024

WASHINGTON, D.C., July 25, 2024—Today, the Biotechnology Innovation Organization (BIO) announced the appointment of longtime biotechnology executive Sylvia Wulf to lead the Agriculture & Environment Center of Excellence (AECOE). The AECOE…

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.